BACKGROUND AND OBJECTIVES: Impaired kidney function is associated with increased risk for cardiovascular disease and may progress over time to end-stage renal disease. Abnormal lipoprotein metabolism has been implicated as a possible cause of these complications, but lipoproteins have not been described at the earliest stages of kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examined cross-sectional associations of serum cystatin C with conventional lipid measurements and detailed nuclear magnetic resonance lipoprotein measurements in the community-based Multi-Ethnic Study of Atherosclerosis. A total of 5109 participants with estimated glomerular filtration rate > or =60 ml/min per 1.73 m(2) were included in analyses. RESULTS: Adjusting for age, gender, race/ethnicity, diabetes, impaired fasting glucose, BP, smoking, medications, body mass index, and albuminuria, greater cystatin C concentrations were associated with progressively unfavorable lipid and lipoprotein concentrations, including greater triglyceride concentration (+22 mg/dl, comparing fifth versus first quintiles of cystatin C) and lesser high-density lipoprotein cholesterol concentration (-7 mg/dl) but not with low-density lipoprotein cholesterol measured using conventional methods. When low-density lipoprotein particle subclasses were examined in more detail using nuclear magnetic resonance, greater cystatin C was associated with greater concentrations of atherogenic small low-density lipoprotein particles (+63 nmol/L) and intermediate-density lipoprotein particles (+6 nmol/L) and with a decrease in mean low-density lipoprotein particle size. CONCLUSIONS: Lipoprotein abnormalities are present with milder degrees of renal impairment than previously recognized, and abnormalities in low-density lipoprotein particle distribution may not be appreciated using conventional lipid measurements. These abnormalities may contribute to kidney disease progression and/or cardiovascular disease.
BACKGROUND AND OBJECTIVES: Impaired kidney function is associated with increased risk for cardiovascular disease and may progress over time to end-stage renal disease. Abnormal lipoprotein metabolism has been implicated as a possible cause of these complications, but lipoproteins have not been described at the earliest stages of kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examined cross-sectional associations of serum cystatin C with conventional lipid measurements and detailed nuclear magnetic resonance lipoprotein measurements in the community-based Multi-Ethnic Study of Atherosclerosis. A total of 5109 participants with estimated glomerular filtration rate > or =60 ml/min per 1.73 m(2) were included in analyses. RESULTS: Adjusting for age, gender, race/ethnicity, diabetes, impaired fasting glucose, BP, smoking, medications, body mass index, and albuminuria, greater cystatin C concentrations were associated with progressively unfavorable lipid and lipoprotein concentrations, including greater triglyceride concentration (+22 mg/dl, comparing fifth versus first quintiles of cystatin C) and lesser high-density lipoprotein cholesterol concentration (-7 mg/dl) but not with low-density lipoprotein cholesterol measured using conventional methods. When low-density lipoprotein particle subclasses were examined in more detail using nuclear magnetic resonance, greater cystatin C was associated with greater concentrations of atherogenic small low-density lipoprotein particles (+63 nmol/L) and intermediate-density lipoprotein particles (+6 nmol/L) and with a decrease in mean low-density lipoprotein particle size. CONCLUSIONS: Lipoprotein abnormalities are present with milder degrees of renal impairment than previously recognized, and abnormalities in low-density lipoprotein particle distribution may not be appreciated using conventional lipid measurements. These abnormalities may contribute to kidney disease progression and/or cardiovascular disease.
Authors: E Coll; A Botey; L Alvarez; E Poch; L Quintó; A Saurina; M Vera; C Piera; A Darnell Journal: Am J Kidney Dis Date: 2000-07 Impact factor: 8.860
Authors: Samia Mora; Moyses Szklo; James D Otvos; Philip Greenland; Bruce M Psaty; David C Goff; Daniel H O'Leary; Mohammed F Saad; Michael Y Tsai; A Richey Sharrett Journal: Atherosclerosis Date: 2007-05 Impact factor: 5.162
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Ian H de Boer; Brad C Astor; Holly Kramer; Walter Palmas; Kyle Rudser; Stephen L Seliger; Michael G Shlipak; David S Siscovick; Michael Y Tsai; Bryan Kestenbaum Journal: Atherosclerosis Date: 2007-08-06 Impact factor: 5.162
Authors: James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart Journal: J Am Soc Nephrol Date: 2014-05-22 Impact factor: 10.121
Authors: Julio A Lamprea-Montealegre; Brad C Astor; Robin L McClelland; Ian H de Boer; Gregory L Burke; Christopher T Sibley; Daniel O'Leary; A Richey Sharrett; Moyses Szklo Journal: Clin J Am Soc Nephrol Date: 2012-08-09 Impact factor: 8.237
Authors: George A Kaysen; Lorien S Dalrymple; Barbara Grimes; Glenn M Chertow; John Kornak; Kirsten L Johansen Journal: Nephrol Dial Transplant Date: 2013-09-05 Impact factor: 5.992
Authors: Anjali Ganda; Martin Magnusson; Laurent Yvan-Charvet; Bo Hedblad; Gunnar Engström; Ding Ai; Thomas J Wang; Robert E Gerszten; Olle Melander; Alan R Tall Journal: Circulation Date: 2013-02-01 Impact factor: 29.690
Authors: N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop Journal: Diabetologia Date: 2009-10-10 Impact factor: 10.122